Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2011-04-05
2011-04-05
Falk, Anne-Marie (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S018000
Reexamination Certificate
active
07919670
ABSTRACT:
The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.
REFERENCES:
patent: 5387742 (1995-02-01), Cordell
patent: 5864018 (1999-01-01), Morser et al.
patent: WO 9726913 (1997-07-01), None
patent: WO 9739121 (1997-10-01), None
patent: WO 9739125 (1997-10-01), None
patent: WO 9822138 (1998-05-01), None
patent: WO 9907402 (1999-02-01), None
patent: WO 9918987 (1999-04-01), None
patent: WO 0020458 (2000-04-01), None
Mullins et al., Transgenesis in Nonmurine Species, 1993, Hypertension, vol. 22, pp. 630-633.
Selkoe, In the beginning . . . , Dec. 12, 1991, Nature, vol. 354, pp. 432-433.
New and Comment, Major Setback for Alzheimer's Models, Science, vol. 255, pp. 1200-1202.
Biotechnology, Aug. 5, 1991, vol. 11, No. 15.
Lannfelt et al., Alzeimer's disease: molecular genetic and transgenic animal models, 1993, Behavioural Brain Research, vol. 57, pp. 207-213.
Houdebine, LM (1994) Production of pharmaceutical proteins from transgenic animals. J. Biotechnology 34: 269-287.
Sigmund (2000) Viewpoint: Are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20: 1425-1429.
Wall, RJ (1996) Transgenic livestock: Progress and prospects for the future. Theriogenology 45: 57-68.
Brett J, Schmidt A-M, Zou Y-S, Yan S-D, Weidman E, Pinsky DJ, Neeper Survey of the Distribution of a Newly Characterized Receptor for Advanced Glycation End Products in Tissues.Am J Pathol1993;143:1699-1712.
Connolly ES, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ: Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia.Neurosurg1996;38:523-532.
Hofmann M, Drury S, Caifeng F, Qu W, Lu Y, Avila C, Kambhan N, Slattery T, McClary J, Nagashima M, Morser J, Stern D, Schmidt A-M: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.Cell1999;97:889-901.
Hori O, Brett J, Nagashima M, Nitecki D, Morser J, Stern DM, Schmidt AM: RAGE is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system.J Biol Chem1995;270:25752-25761.
Hsia A, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K, Kholodenkc D, Malenka R, Nicoll R, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.Proc Natl Acad Sci(USA) 1999;96:3228-3233.
Nakashima Y, Plump A, Raines E, Breslow J, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.Arterioscler Thromb1994;141:133-140.
Neeper et al, J. Biol. Chem., 267:14998-15004, 1992
Park L, Raman K, Lee K, Lu Y, Ferran L, Chow W-S, Stern D, Schmidt A-M: Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE).Nature Med1998;4:1025-1031.
Schmidt et al, J. Biol. Chem., 267:14987-97, 1992.
Schmidt A-M, Yan S-D, Wautier J-L, Stern DM: Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis.Circ Res1999;84:489-497.
Stern et al. U.S. Appl. No. 09/638,649, filed Aug. 14, 2000, A Model of Alzheimer's-type Pathology Double Transgenic Mice, RAGE + Mutant APP.
White A, Zheng H, Galatis D, Maher F, Hesse L, Multhaup G, Beyreuther K, Masters C, Cappai R: Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer's amyloid-β, toxicity and oxidative stress.J Neurosci1998;18:6207-6217.
Yan S-D, Zhu H, Zhu A, Golabek A, Roher A, Yu J, Soto C, Schmidt A-M, Stern DM, Kindy M: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.Nat Med2000;6:643-651.
Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt A-M: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.Nature1996;382:685-691.
Schmidt Ann Marie
Stern David M.
Yan Shi Du
Cooper & Dunham LLP
Falk Anne-Marie
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Transgenic mice over-expressing receptor for advanced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mice over-expressing receptor for advanced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mice over-expressing receptor for advanced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684102